Background: Crohn's disease (CD) is a long-term inflammatory condition of the digestive system. People with CD often have unpredictable and debilitating symptoms, including abdominal pain, diarrhoea and fatigue. In addition, they require long-term treatment with frequent negative effects and often need surgery and hospitalisations. Therefore, people with CD report a lower health-related quality of life (HRQOL) compared with other people. Doctors are constantly trying to find new treatments to improve HRQOL and control symptoms and whole body vibration exercise could be a potential treatment. Exercise might be a simple, safe, and low-cost intervention for improving HRQOL in people with CD. This is because it has the potential to improve several aspects of physical, mental and social well-being simultaneously. Adults with CD have been shown to be less active than the general population and do not meet the recommended daily physical activity guidelines. One barrier to exercise is lack of time, however whole-body vibration exercise (where you stand and squat on a vibrating plate) can be done over a much shorter duration and at a lower intensity to gain potentially similar or at times greater benefits. More research is needed to understand the effects, both positive and negative of vibration exercise in people with CD. Aim: This study begins to understand whether undertaking a supervised 6-week vibration exercise programme for adults with mild to moderately active Crohn's disease improves HRQoL and other symptoms such as fatigue.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Enrollment
168
6-week supervised whole body vibration exercise programme (training sessions three times per week lasting 10 min) alongside a lifestyle education programme
University of Hertfordshire
Hatfield, UK, United Kingdom
RECRUITINGInflammatory Bowel Disease Questionnaire (IBDQ)
The scale has 32 items scored on a 7-point Likert scale, ranging from 1 (worst health) to 7 (best health).
Time frame: change in IBDQ from baseline to 6 weeks
Crohn's disease activity index (CDAI)
CDAI is a clinically assessed measure of disease activity in Crohn's patients. The score ranges from 0-600 with higher scores being indicative of higher disease activity
Time frame: change in CDAI from baseline to 6 weeks
Concentration of Faecal Calprotectin (FC)
a marker of inflammation in the gastrointestinal tract. Higher levels are indicative of higher inflammation levels
Time frame: change in FC from baseline to 6 weeks
Inflammatory Bowel Disease Fatigue (IBD Fatigue)
The IBD Fatigue Scale is comprised of two components. Part 1 the questionnaire will identify fatigue, its severity, frequency and duration and scores range from 0-20 with a higher score meaning greater fatigue. Part 2 assesses the perceived impact of fatigue on your daily activities and scores range from 0-120 with a higher score meaning greater perceived impact.
Time frame: change in IBD fatigue from baseline to 6 weeks
Hospital Anxiety and Depression (HADS)
The Hospital Anxiety and Depression Scale measures anxiety and depression in patients. A higher score indicates greater anxiety and depression.
Time frame: change in HADS from baseline to 6 weeks
Perceived pain
visual analogue scale from 0-10, 0 being no pain and 10 being most intense pain possible
Time frame: change in pain from baseline to 6 weeks
Estimated Cardiorespiratory fitness
Chester step test to estimate maximal oxygen consumption. It involves stepping in time to a metronome and measuring heart rate.
Time frame: change in estimated maximal oxygen consumption from baseline to 6 weeks
Concentration of Tnf-alpha
This measure will be obtained from blood samples to provide a measure of inflammation
Time frame: change from baseline to 6 weeks
Concentration of Interleukin-6 (IL6)
This measure will be obtained from blood samples to provide a measure of inflammation
Time frame: change from baseline to 6 weeks
Concentration of Interleuken-10 (IL10)
This measure will be obtained from blood samples to provide a measure of inflammation
Time frame: change from baseline to 6 weeks
Concentration of Interleukin 17a (IL17a)
This measure will be obtained from blood samples to provide a measure of inflammation
Time frame: change from baseline to 6 weeks
Concentration of Interleukin 12 (IL12)
This measure will be obtained from blood samples to provide a measure of inflammation
Time frame: change from baseline to 6 weeks
Concentration of Interleukin 23 (IL23)
This measure will be obtained from blood samples to provide a measure of inflammation
Time frame: change from baseline to 6 weeks
Concentration of Transforming Growth Factor Beta (TGF-Beta)
This measure will be obtained from blood samples to provide a measure of inflammation
Time frame: change from baseline to 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.